Low-Moisture HPMC Capsule Shell for 5-ASA Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
5-aminosalicylic acid dosage forms are prone to degradation when formulated with reducing sugars and exposed to high humidity, leading to the formation of degradants that reduce shelf life and product performance, and existing encapsulation methods do not effectively address this issue.
Innovation Solution
A capsule dosage form with an enterically coated tablet of 5-aminosalicylic acid or its salt, where the capsule shell has a low moisture content (<10% by weight) and is made of materials like HPMC, providing improved handling and stability by inhibiting degradant formation and maintaining the drug's delivery profile during storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 5-aminosalicylic acid is formulated with reducing sugars and stored in high humidity conditions, then the dosage form can be manufactured and handled, but degradation occurs leading to degradant formation that reduces shelf life and product performance
Solution Approach 1:
The patent introduces an intermediary protective layer (enteric coating on tablets and capsule shell) that mediates between the 5-aminosalicylic acid formulation and the harmful humid environment. This coating acts as a barrier that prevents direct interaction between moisture and the degradation-prone formulation, thereby eliminating degradant formation while maintaining shelf life
Solution Approach 2:
The enteric coating creates an inert protective environment around the 5-aminosalicylic acid tablets, isolating them from harmful external conditions (humidity and light). This inert barrier prevents the chemical reactions that would otherwise occur between the formulation and environmental factors, thus preventing degradation and extending shelf life
2Ease of operation
If conventional encapsulation methods are used, then handling is improved, but stability and degradant formation control are not effectively addressed
Solution Approach 1:
The patent employs composite materials consisting of multiple layers with different functions: the enteric coating layers provide stability and protection against degradation, while the capsule shell provides ease of handling and patient compliance. This composite structure integrates both requirements that conventional single-material encapsulation could not satisfy simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The low-moisture capsule shell enhances the stability of enterically coated 5-aminosalicylic acid tablets, reducing degradant formation and maintaining the drug's release profile, thereby extending shelf life and ensuring effective delivery to the colon.
Implementation Method 1
a capsule shell having less than about 10% by weight moisture content in the capsule shell at a relative humidity of 60% and a temperature of 25° C.
Implementation Method 2
enterically coated to facilitate delivery of the active ingredient to the colon
Data Source
AI summary
A dosage form comprising a capsule containing one or more tablets of 5-aminosalicylic acid or a salt thereof as an active ingredient where each of the one or more tablets is enterically coated is disclosed.